Core Viewpoint - The article discusses the significant investment by Zhong Shanshan in Jinbo Biological, a company specializing in recombinant collagen products, highlighting the potential for growth in the medical beauty industry and the strategic collaboration between the two entities [4][6][12]. Group 1: Investment Details - Jinbo Biological announced two transactions, including introducing Yangshengtang as a strategic investor, with a total transaction amount reaching 3.4 billion yuan [5][8]. - The strategic investment involves issuing up to 7.1757 million shares, representing 6.24% of the pre-issue total share capital, aiming to raise no more than 2 billion yuan [8]. - Yang Xia, the founder of Jinbo Biological, transferred 5.7533 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [9][10]. Group 2: Company Background - Jinbo Biological, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [6][18]. - The company has developed a range of products, including recombinant type III collagen, which has been widely adopted in medical and cosmetic applications [22][23]. - Jinbo Biological's revenue for 2024 is projected to be 1.443 billion yuan, reflecting a year-on-year growth of 84.92%, with a net profit of 732 million yuan, marking an increase of over 140% [23]. Group 3: Market Dynamics - The medical beauty industry, particularly the recombinant collagen segment, is experiencing rapid growth, with high consumer interest and significant market potential [26][30]. - The article notes that the pursuit of beauty is a strong driver for repeat purchases, making this sector highly lucrative [30]. - Jinbo Biological's products have gained popularity, with its core product, the injectable recombinant type III collagen, being used in over 4,000 medical institutions [23][24].

Core Viewpoint - Ju宜 Group has officially signed an acquisition agreement with the dermatological skincare brand 百植萃, aiming to strengthen its position in the scientific skincare sector [1][9]. Company Overview - 百植萃 was established in 2012, focusing on providing safe and effective skincare solutions for problematic and sensitive skin, with a product line that includes soothing, barrier repair, anti-aging, and whitening [3]. - The brand's best-selling product is the 小绿瓶精华, priced at 198 yuan for 30ml, 288 yuan for 50ml, and 458 yuan for 80ml, with previous prices being significantly higher [3]. Leadership and Expertise - The brand's product development has been led by renowned dermatologist 李远宏, who has contributed to the formulation of all products and has internationally recognized research achievements [7]. - 李远宏 will continue as Chief Product Officer post-acquisition, overseeing the entire product development process from consumer insights to clinical validation [9]. Market Position and Strategy - Ju宜 Group sees long-term growth potential in the "medical-research integration" skincare sector, which addresses real pain points for different skin types and represents a significant direction for skincare consumption upgrades [9]. - The acquisition is viewed as a strategic move to fill gaps in the skincare market and enhance Ju宜 Group's portfolio, following its previous acquisition of the high-end hair care brand馥绿德雅 [9]. Financial Performance - Ju宜 Group reported a revenue of 3.5 billion yuan in 2024, marking a 36% year-on-year growth, and has maintained double-digit growth for several consecutive years [11]. - The acquisition of 百植萃 is interpreted as a step towards seeking a larger premium space in the market, especially as the functional skincare market becomes increasingly competitive among major beauty brands [11]. Industry Trends - The functional skincare market is becoming a battleground for beauty giants, with companies like L'Oréal and Estée Lauder increasing their investments in this area [11]. - Recent acquisitions in the sector, such as L'Oréal's purchase of Medik8, highlight the trend of integrating scientific research into skincare product development [11].

Core Insights - The acquisition of Baizhichui by Juyi Group marks a significant step in the company's strategy to expand into the scientific skincare sector, enhancing its multi-brand and multi-category beauty matrix [1][4] - The global functional skincare market is experiencing intense competition, with both international giants and local brands accelerating their presence in this lucrative segment [6][7] Company Overview - Juyi Group, established in 2016 and headquartered in Shanghai, owns two major color cosmetics brands, Judydoll and Jooycee, and has a partnership with Pierre Fabre Laboratories for the René Furterer brand in China [4] - The group reported a retail revenue exceeding 4.2 billion yuan and an income of 3.5 billion yuan in 2024, reflecting a year-on-year growth of 36% [4] Acquisition Details - Baizhichui, founded in 2012 and part of Meiji Biotechnology (Shanghai) Co., focuses on providing solutions for problematic and sensitive skin, emphasizing a "plant + technology" research approach [4][5] - Post-acquisition, Professor Li Yuanhong will continue as Chief Product Officer, overseeing the entire product development process, while co-founder and CEO Sun Hui will serve as a lifetime honorary advisor [5] Market Trends - The global professional skincare market reached a size of $35.77 billion in 2022, with projections to exceed $77.51 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9% [6] - In China, the functional skincare sector saw a CAGR of 36.7% from 2017 to 2021, with a market size of approximately 46.43 billion yuan in 2022, marking a year-on-year growth of 22.9% [6] Competitive Landscape - Major global beauty companies like L'Oréal and Estée Lauder are increasingly investing in functional skincare through acquisitions and partnerships, indicating a strategic shift towards professional medical beauty [7][8] - Local brands such as Winona and Juzi Biotechnology are also capturing market share through differentiated strategies, with Juzi Biotechnology reporting a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2% [8]